John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Adjuvant treatment of biliary tract cancers: who and how? Volume 27, supplement 6, Décembre 2020

Figures

  • Figure 1

Tables

Author
Centre Eugène Marquis, Service d’oncologie médicale, Avenue de la Bataille Flandres-Dunkerque, 35000 Rennes
* Correspondance

The adjuvant treatment of biliary tract cancers has long been poorly defined. In recent years, randomized trial data have been used to define treatment references. The French PRODIGE 12 and Japanese BCAT trials have not demonstrated any benefit of adjuvant chemotherapy. The English BILCAP trial tested adjuvant capecitabine for 6 months at the usual dose in a randomized, controlled-only trial involving 447 patients. Although the results in intention to treat were borderline significant on the primary endpoint, overall survival (p = 0.097), sensitivity analyzes adjusted for prognostic factors and relapse-free survival analyses are clearly positive. The absolute benefit of +5%/+10% overall survival, combined with low and known toxicity profile, lead to recommending treatment for any cancer of the resected bile ducts (with the exception of gallbladder cancer pT1).